title: Suppression of estrogen-withdrawal headache with extended transdermal contraception.
abstract: A randomized clinical trial was conducted with 239 women at nine clinical research sites to compare bleeding profile, headache frequency, and subject satisfaction with the transdermal contraceptive, ORTHO EVRA (norelgestromin/ethinyl estradiol transdermal system) used in an extended regimen (84 days) with a traditional, 28-day cyclic regimen. In a majority of women studied, compared with cyclic use, extended use of transdermal norelgestromin/ethinyl estradiol delayed menses and reduced the total incidence of mean headache days during the hormone-free interval.
authors.affiliation: Clinical Affairs, Ortho-McNeil Pharmaceutical, Inc., Raritan, New Jersey 08869, USA. klaguard@ompus.jnj.com
authors.forename: Katherine D
authors.initials: KD
authors.lastname: LaGuardia
authors.forename: Alan C
authors.initials: AC
authors.lastname: Fisher
authors.forename: James D
authors.initials: JD
authors.lastname: Bainbridge
authors.forename: John M
authors.initials: JM
authors.lastname: LoCoco
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Friedman
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D005003:Ethisterone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006261:Headache / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D009644:Norgestrel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010091:Oximes / Q000008:administration & dosage; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000517:prevention & control; D013997:Time Factors
chemical_list: D003692:Delayed-Action Preparations; D004338:Drug Combinations; D010091:Oximes; D009644:Norgestrel; D005003:Ethisterone; C449219:norelgestromin